Copenhagen, 10 August 2010 - Today, NeuroSearch A/S (NEUR) announced that one
of the company's associated companies, NsGene A/S (26.8 percent owned) has
executed a new and expanded license and commercialisation agreement with Biogen
Idec (NASDAQ: BIIB) on Neublastin. Neublastin is a novel and potentially
disease-modifying therapeutic protein currently in Phase I development for the
treatment of neuropathic pain under the agreement with Biogen Idec.

The expanded agreement grants Biogen Idec extended rights to Neublastin and
secures NsGene an upfront payment of USD 6 million, and an annual maintenance
fee of USD 1.5 million. The maintenance fee is to be paid in those years in
which NsGene does not receive a development milestone and until acceptance of
the first regulatory filing for approval of a Neublastin product. In addition,
NsGene will receive increased royalties on future sales of Neublastin products.
Development milestones will be paid in accordance with the agreement from year
2000.

Flemming Pedersen, CEO of NeuroSearch, commented:
"We are very pleased to have part in NsGene and the company's exciting
portfolio of novel and unique therapeutic proteins. We see strong value
potential in disease modifying treatment of neurological diseases and believe
NsGene to be well positioned in the field. The expanded agreement with Biogen
Idec in our view further validates Neublastin and thereby also the business of
NsGene in broader terms."

For further information, see attached press release from NsGene.

Thomas Hofman-Bang Flemming Pedersen
Chairman CEO

Contact person:

Flemming Pedersen, CEO, telephone; +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone; +45 4460 8212 or +45 4017 5103

About NeuroSearch - Company profile
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel treatment of obesity.

NeuroSearch is founded on a well-established drug discovery platform in the
field of small molecule pharmacology, ion channels and monoamine transporters,
leading to the continuous production of novel preclinical development
candidates. The company has strategic drug discovery alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
Further, NeuroSearch has equity interests in a number of private health care
companies.

-------------------------------

Ballerup, Denmark, August 10th, 2010

PRESS RELEASE

NsGene and Biogen Idec sign new commercialisation and license agreement on
Neublastin, a novel therapeutic protein in clinical development for neuropathic
pain

NsGene A/S today announced that Biogen Idec [NASDAQ: BIIB] and NsGene have
executed a new and expanded agreement, which grants Biogen Idec exclusive
global rights to commercialise Neublastin for all indications, and in all
formulations. This agreement enables Biogen Idec to develop all Neublastin
product opportunities and replaces a license and collaboration agreement from
year 2000 under which Neublastin has been successfully brought into Phase I
clinical development for the treatment of neuropathic pain. NsGene will receive
development milestone payments in accordance with the agreement from year 2000.
The expanded agreement secures NsGene an upfront payment of USD 6 million, and
an annual maintenance fee of USD 1.5 million until acceptance of the first
regulatory filing for approval with respect to a Neublastin product. The
maintenance fee will be paid in those years in which NsGene does not receive a
development milestone. In addition, NsGene will receive increased royalties on
future sales of Neublastin products.

Teit E. Johansen, CEO of NsGene, said, ?NsGene is pleased to hand over the full
control of the commercialisation of Neublastin to Biogen Idec. We are convinced
that Biogen Idec is the right partner to fully exploit the value of this
exciting molecule. This agreement is further evidence that our unique pipeline
of proprietary neurotrophic factors continues to add value to NsGene and its
shareholders?.

Lars U. Wahlberg, COO of NsGene, added, ?We are proud that Neublastin continues
to be one of the most promising and exciting product opportunities for the
treatment of neuropathy and associated pain. Biogen Idec remains a strong and
committed partner and this new agreement enables a much broader range of
Neublastin product opportunities to be exploited in capable hands?.

Neublastin is a novel and potentially disease-modifying therapeutic protein for
the treatment of neuropathic pain that afflicts millions of people worldwide.
Neuropathic pain is a major debilitating consequence of nerve damage and
existing treatments are largely ineffective. Neuropathic pain is commonly
caused by diabetes and herpes zoster infection. Other causes are amputation,
failed back syndromes, cancer-induced nerve compression and chemotherapy.


For further information please contact:
Teit E. Johansen, President & CEO
Telephone: +45 44 60 89 48; Fax: +45 44 60 89 89
E-mail: [email protected]

NsGene A/S Background
NsGene A/S (www.nsgene.dk) is a privately held Danish biotechnology company
founded in 1999 as a spin-off from NeuroSearch A/S [OMX Nordic: NEUR]. NsGene
develops new therapies for neurological diseases with high needs for
efficacious treatments, including Alzheimer's disease, Parkinson's disease,
Huntington's disease, and intractable epilepsy. Established and novel proteins,
including antibodies, can be delivered to the brain with NsGene's competitive
and proprietary EC Biodelivery? platform. NsGene's development pipeline
includes clinical and late-stage preclinical novel biological therapeutics.

The major shareholders of NsGene include NeuroSearch A/S, Sunstone Capital A/S,
Omega Funds, and LD Pensions.